|Dr. Amber Salzman Ph.D.||Chief Exec. Officer, Pres and Director||442.82k||N/A||55|
|Dr. Mitchell H. Finer Ph.D.||Co-Founder and Director||57.48k||N/A||58|
|Dr. Mehdi Gasmi Ph.D.||Chief Science and Technology Officer||634.14k||N/A||50|
|Ms. Leone D. Patterson||Chief Financial Officer||N/A||N/A||54|
|Mr. Charles Butler||VP of Investor Relations & Corp. Communications||N/A||N/A||N/A|
Adverum Biotechnologies, Inc., a gene therapy company, discovers and develops novel medicines for patients suffering from rare diseases or diseases of eye. The company has a pipeline that includes product candidates to treat wet age-related macular degeneration (wAMD), alpha 1 antitrypsin deficiency (A1AT), and hereditary angioedema. Its lead gene therapy programs include ADVM-022 and ADVM-032, which are in the preclinical development of new anti-VEGF gene therapy candidates for wAMD diseases; and ADVM-043, which is in patient enrollment in a phase 1/2 trial for the treatment of A1AT. The company is also developing ADVM-053 to treat hereditary angioedema; and other product candidates, such as ocular therapeutics, including AVA-311 for the treatment of juvenile X-linked retinoschisis. It has collaboration agreements with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize gene therapy products for ophthalmic diseases; and Editas Medicine, Inc. to explore the delivery of genome editing medicines for the treatment of inherited retinal diseases. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was founded in 2006 and is headquartered in Menlo Park, California.
Adverum Biotechnologies, Inc.’s ISS Governance QualityScore as of December 1, 2017 is 10. The pillar scores are Audit: 2; Board: 9; Shareholder Rights: 8; Compensation: 9.